Literature DB >> 17459936

Epstein-Barr virus entry.

Lindsey M Hutt-Fletcher1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17459936      PMCID： PMC1951282          DOI： 10.1128/JVI.00445-07

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


× No keyword cloud information.
  70 in total

1.  Inhibition of Epstein-Barr virus infection in vitro and in vivo by soluble CR2 (CD21) containing two short consensus repeats.

Authors:  M D Moore; M J Cannon; A Sewall; M Finlayson; M Okimoto; G R Nemerow
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

2.  Production and characterization of monoclonal antibodies against the Epstein-Barr virus membrane antigen.

Authors:  B C Strnad; T Schuster; R Klein; R F Hopkins; T Witmer; R H Neubauer; H Rabin
Journal:  J Virol       Date:  1982-01       Impact factor: 5.103

3.  Early events in the infection of human B lymphocytes by Epstein-Barr virus: the internalization process.

Authors:  G R Nemerow; N R Cooper
Journal:  Virology       Date:  1984-01-15       Impact factor: 3.616

4.  An Epstein-Barr virus DNA fragment encodes messages for the two major envelope glycoproteins (gp350/300 and gp220/200).

Authors:  M Hummel; D Thorley-Lawson; E Kieff
Journal:  J Virol       Date:  1984-02       Impact factor: 5.103

5.  Depletion of glycoprotein gp85 from virosomes made with Epstein-Barr virus proteins abolishes their ability to fuse with virus receptor-bearing cells.

Authors:  R S Haddad; L M Hutt-Fletcher
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

6.  Capacity of Epstein-Barr virus to infect monocytes and inhibit their development into dendritic cells is affected by the cell type supporting virus replication.

Authors:  Andre Ortlieb Guerreiro-Cacais; LiQi Li; Daria Donati; Maria Teresa Bejarano; Andrew Morgan; Maria G Masucci; Lindsey Hutt-Fletcher; Victor Levitsky
Journal:  J Gen Virol       Date:  2004-10       Impact factor: 3.891

7.  Use of gHgL for attachment of Epstein-Barr virus to epithelial cells compromises infection.

Authors:  Corina M Borza; Andrew J Morgan; Susan M Turk; Lindsey M Hutt-Fletcher
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Mutational analyses of Epstein-Barr virus glycoprotein 42 reveal functional domains not involved in receptor binding but required for membrane fusion.

Authors:  Amanda L Silva; Jasmina Omerovic; Theodore S Jardetzky; Richard Longnecker
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

9.  EBV attachment stimulates FHOS/FHOD1 redistribution and co-aggregation with CD21: formin interactions with the cytoplasmic domain of human CD21.

Authors:  Michael B Gill; Jennifer Roecklein-Canfield; David R Sage; Maria Zambela-Soediono; Nina Longtine; Marc Uknis; Joyce D Fingeroth
Journal:  J Cell Sci       Date:  2004-05-11       Impact factor: 5.285

10.  Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis.

Authors:  H F Weisman; T Bartow; M K Leppo; H C Marsh; G R Carson; M F Concino; M P Boyle; K H Roux; M L Weisfeldt; D T Fearon
Journal:  Science       Date:  1990-07-13       Impact factor: 47.728
View more
  129 in total

1.  Crystal structure of the Epstein-Barr virus (EBV) glycoprotein H/glycoprotein L (gH/gL) complex.

Authors:  Hisae Matsuura; Austin N Kirschner; Richard Longnecker; Theodore S Jardetzky
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-13       Impact factor: 11.205

2.  Fusion of Epstein-Barr virus with epithelial cells can be triggered by αvβ5 in addition to αvβ6 and αvβ8, and integrin binding triggers a conformational change in glycoproteins gHgL.

Authors:  Liudmila S Chesnokova; Lindsey M Hutt-Fletcher
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

Review 3.  Infectious Mononucleosis.

Authors:  Samantha K Dunmire; Kristin A Hogquist; Henry H Balfour
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

4.  Specialization for Cell-Free or Cell-to-Cell Spread of BAC-Cloned Human Cytomegalovirus Strains Is Determined by Factors beyond the UL128-131 and RL13 Loci.

Authors:  Eric P Schultz; Jean-Marc Lanchy; Le Zhang Day; Qin Yu; Christopher Peterson; Jessica Preece; Brent J Ryckman
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

5.  Impact of selective CD28 blockade on virus-specific immunity to a murine Epstein-Barr virus homolog.

Authors:  Rebecca L Crepeau; Joseph A Elengickal; Glenn M La Muraglia; Mandy L Ford
Journal:  Am J Transplant       Date:  2019-03-29       Impact factor: 8.086

6.  Cleavage of Epstein-Barr virus glycoprotein B is required for full function in cell-cell fusion with both epithelial and B cells.

Authors:  Jessica Sorem; Richard Longnecker
Journal:  J Gen Virol       Date:  2009-03       Impact factor: 3.891

7.  Protein array identification of substrates of the Epstein-Barr virus protein kinase BGLF4.

Authors:  Jian Zhu; Gangling Liao; Liang Shan; Jun Zhang; Mei-Ru Chen; Gary S Hayward; S Diane Hayward; Prashant Desai; Heng Zhu
Journal:  J Virol       Date:  2009-02-25       Impact factor: 5.103

8.  Primary B-cell infection with a deltaBALF4 Epstein-Barr virus comes to a halt in the endosomal compartment yet still elicits a potent CD4-positive cytotoxic T-cell response.

Authors:  Bernhard Neuhierl; Regina Feederle; Dinesh Adhikary; Birgit Hub; Karsten Geletneky; Josef Mautner; Henri-Jacques Delecluse
Journal:  J Virol       Date:  2009-02-25       Impact factor: 5.103

9.  Equine herpesvirus 1 entry via endocytosis is facilitated by alphaV integrins and an RSD motif in glycoprotein D.

Authors:  Gerlinde R Van de Walle; Sarah T Peters; Brian C VanderVen; Dennis J O'Callaghan; Nikolaus Osterrieder
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

10.  Functions of the unique N-terminal region of glycoprotein E in the pathogenesis of varicella-zoster virus infection.

Authors:  Barbara Berarducci; Jaya Rajamani; Leigh Zerboni; Xibing Che; Marvin Sommer; Ann M Arvin
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.